Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.

por Hilkens, P. H., Pronk, L. C., Verweij, J., Vecht, C. J., van Putten, W. L., van den Bent, M. J.
Publicado 1997

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

por Pronk, L C, Vasey, P, Sparreboom, A, Reigner, B, Planting, A S Th, Gordon, R J, Osterwalder, B, Verweij, J, Twelves, C
Publicado 2000

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.

por Pronk, L. C., Schrijvers, D., Schellens, J. H., de Bruijn, E. A., Planting, A. S., Locci-Tonelli, D., Groult, V., Verweij, J., van Oosterom, A. T.
Publicado 1998

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

por Attard, G, Kitzen, J, Blagden, S P, Fong, P C, Pronk, L C, Zhi, J, Zugmaier, G, Verweij, J, de Bono, J S, de Jonge, M
Publicado 2007

Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.

por Stouthard, J. M., Goey, H., de Vries, E. G., de Mulder, P. H., Groenewegen, A., Pronk, L., Stoter, G., Sauerwein, H. P., Bakker, P. J., Veenhof, C. H.
Publicado 1996

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial

por Rohaan, M.W., Gomez-Eerland, R., van den Berg, J.H., Geukes Foppen, M.H., van Zon, M., Raud, B., Jedema, I., Scheij, S., de Boer, R., Bakker, N.A.M., van den Broek, D., Pronk, L.M., Grijpink-Ongering, L.G., Sari, A., Kessels, R., van den Haak, M., Mallo, H.A., Karger, M., van de Wiel, B.A., Zuur, C.L., Duinkerken, C.W., Lalezari, F., van Thienen, J.V., Wilgenhof, S., Blank, C.U., Beijnen, J.H., Nuijen, B., Schumacher, T.N., Haanen, J.B.A.G.
Publicado 2022